未知生产厂商
Porustobart (also known as HBM4003) is a second-generation, Fc-enhanced CTLA-4 antibody being developed by Solstice Oncology for the neoadjuvant treatment of microsatellite-stable (MSS) clinical stage II-III colon cancer; it is being evaluated in a Phase 2 trial in combination with pembrolizumab.
Porustobart (also known as HBM4003) is a second-generation, Fc-enhanced CTLA-4 antibody being developed by Solstice Oncology for the neoadjuvant treatment of microsatellite-stable (MSS) clinical stage II-III colon cancer; it is being evaluated in a Phase 2 trial in combination with pembrolizumab.
Porustobart is a differentiated, second-generation, Fc-enhanced cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
